IGC Pharma
21 hedge funds and large institutions have $694K invested in IGC Pharma in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 6 closing their positions.
500% more call options, than puts
Call options by funds: $6K | Put options by funds: $1K
0.4% less ownership
Funds ownership: 4.03% → 3.63% (-0.4%)
19% less funds holding
Funds holding: 26 → 21 (-5)
31% less capital invested
Capital invested by funds: $1M → $694K (-$308K)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$33.4K |
| 2 |
Wells Fargo
San Francisco,
California
|
+$126 |
| 3 |
GSWM
Golden State Wealth Management
Santa Ana,
California
|
+$125 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$68 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
-$57K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$6.92K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$6K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$1.79K |
IGC Hedge Fund Activity: Q1 2020 in Review
21 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in IGC Pharma (IGC) for Q1 2020, worth a combined $694K — down 31% from $1M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of IGC and 4 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was BlackRock, adding an estimated $33.4K. The largest seller was Creative Planning, exiting entirely with an estimated $57K sold.
- 21 institutional investors held IGC Pharma (IGC) as of Q1 2020, down from 26 in Q4 2019.
- Funds reported $694K of IGC Pharma stock for Q1 2020, down 31% quarter-over-quarter.
- 4 funds opened new IGC Pharma positions in Q1 2020 and 6 closed out, a net change of -2 holders.
- The largest IGC Pharma buyer in Q1 2020 was BlackRock, an estimated $33.4K added.
- The largest IGC Pharma seller in Q1 2020 was Creative Planning, an estimated $57K sold.
Based on aggregated 13F filings for Q1 2020.